

I. AMENDMENTS

A. In the Claims

This listing of claims replaces all prior versions and listings of claims in the application.

1. (Currently Amended) A method of inhibiting inflammation ~~within an immune privileged site in an animal in the central nervous system in a patient diagnosed with multiple sclerosis~~ comprising delivering an effective amount of a compound consisting essentially of a soluble Fas ligand fragment to the patient, behind the blood-tissue barrier of the immune privileged site, wherein said ~~soluble Fas ligand fragment has the ability to induce apoptosis in Fas-expressing cells~~ compound is delivered into the cerebrospinal fluid by a method selected from the group consisting of intrathecal administration, intraventricular administration, and intracisternal administration.

2. (Canceled).

3. (Canceled).

4. (Previously Presented) The method according to claim 1, wherein said soluble Fas ligand fragment is a recombinant polypeptide.

5. (Previously Presented) The method according to claim 1, wherein said soluble Fas ligand fragment consists essentially of amino acids 103-281 of a human full length Fas ligand.

Claims 6-15. (Canceled).

In re Application of:

Zhu et al.

Application No.: 09/927,110

Filed: August 10, 2001

Page 4

PATENT

Attorney Docket No.: SMART1240

16. (Currently Amended) The method according to claim ~~15~~1, wherein said ~~animal~~
patient is a human.

Claims 17-57 (Canceled).

58. (Currently Amended) The method of claim 1, wherein said soluble Fas ligand
fragment ~~comprises~~ consists essentially of the extracellular domain of a full length Fas ligand.

Claims 59-61 (Canceled).

62. (New) The method of claim 1, wherein the multiple sclerosis is
relapsing/remitting multiple sclerosis.